Photo from wikipedia
Key Points Question Is there an association between dynamic measurable residual disease, treatment, and outcomes among adults with intermediate-risk acute myeloid leukemia? Findings In this registry-based cohort study that included… Click to show full abstract
Key Points Question Is there an association between dynamic measurable residual disease, treatment, and outcomes among adults with intermediate-risk acute myeloid leukemia? Findings In this registry-based cohort study that included 549 younger patients (aged 14-60 years) with intermediate-risk acute myeloid leukemia, 154 received chemotherapy, 116 received an autologous stem cell transplant, and 279 received an allogeneic stem cell transplant. Results showed that making a postremission treatment choice based on dynamic measurable residual disease was associated with improved outcomes in subgroup analyses. Meaning This study suggests that clinical decisions based on dynamic measurable residual disease might be associated with improved therapy stratification and optimized postremission treatment for patients with intermediate-risk acute myeloid leukemia.
Journal Title: JAMA Network Open
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!